share_log

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed獲准延期180天以滿足納斯達克最低出價要求
InMed Pharmaceuticals ·  03/20 12:00

Vancouver, British Columbia–(Newsfile Corp. – March 20, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a notification letter from the Listing Qualifications Department of Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the "Extended Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule").

不列顛哥倫比亞省溫哥華——(Newsfile Corp.,2024年3月20日)——稀有大麻素和專有大麻素類似物製造、開發和商業化的領導者InMed Pharmicals Inc.(納斯達克股票代碼:INM)(“InMed” 或 “公司”)今天宣佈,它已收到納斯達克股票市場有限責任公司(“納斯達克”)上市資格部的通知信,該公司已獲得額外授權 180 天合規期,或直到 2024 年 9 月 16 日(“延長合規期”),以恢復對納斯達克的合規性根據《納斯達克上市規則》5550(a)(2)(“最低出價規則”)的規定,繼續在納斯達克資本市場上市的最低出價要求。

Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to consider all available options to regain compliance during the Extended Compliance Period, including, if necessary, effecting a reverse stock split.

納斯達克的決定是基於公司滿足公開持股市值的持續上市要求以及在納斯達克資本市場首次上市的所有其他適用要求,但出價要求除外,以及公司關於打算在延長的合規期內考慮所有可用選擇以恢復合規性的書面通知,包括在必要時進行反向股票拆分。

If at any time prior to September 16, 2024, the closing bid price of the Company's ordinary shares is at least $1.00 per share for at least a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Price Rule and this matter will be closed.

如果在2024年9月16日之前的任何時候,至少連續10個工作日內,公司普通股的收盤價爲每股1.00美元,則公司將恢復對最低出價規則的遵守,此事將結案。

As previously reported, in a notification letter dated September 19, 2023, Nasdaq had informed the Company that, based on the previous 30 consecutive business days, the Company's ordinary shares no longer met the minimum $1.00 bid price per share requirement as set forth in the Minimum Bid Price Rule. Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until March 18, 2024, to regain compliance with such requirement.

正如先前報道的那樣,納斯達克在2023年9月19日的通知信中告知公司,根據之前的連續30個工作日,該公司的普通股不再符合最低出價規則中規定的每股1.00美元的最低出價要求。因此,根據納斯達克上市規則,公司有180個日曆日或直到2024年3月18日才能恢復對此類要求的遵守。

This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "INM."

納斯達克當前的通知對公司普通股的上市或交易沒有立即影響,普通股將繼續在納斯達克資本市場上交易,股票代碼爲 “INM”。

About InMed:
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with our subsidiary, BayMedica LLC, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

關於 inMed:
InMed Pharmaceuticals是稀有大麻素和專有大麻素類似物的製造、開發和商業化的全球領導者。與我們的子公司BayMedica LLC一起,我們擁有無與倫比的大麻素製造能力,可以爲包括製藥、健康和保健在內的一系列消費市場提供服務。我們是一家處於臨床階段的公司,正在開發一系列稀有的大麻素療法,致力於爲可能受益於大麻素類藥物的患者提供新的治療替代方案。欲了解更多信息,請訪問 www.inmedpharma.com

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: [email protected]

投資者聯繫人:
科林·克蘭西
投資者關係副總裁
和企業傳播
電話:+1 604 416 0999
E: [電子郵件保護]

Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. This news release contains forward-looking statements, including, but not limited to, statements regarding the Company's ability to regain compliance with the Minimum Bid Price Rule, the Company's intention to monitor closing bid prices of its ordinary shares and the Company's plans to consider implementing available options to regain compliance with the Minimum Bid Price Rule, including, if necessary, effecting a reverse stock split. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of known and unknown risks and uncertainties, including the risk that (i) the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, (ii) the Company may not meet the Minimum Bid Price Rule during the Extended Compliance Period or any other compliance period in the future, (iii) Nasdaq may not grant the Company relief from delisting, if necessary, and (iv) the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties.

關於前瞻性信息的警示說明:
本新聞稿包含經修訂的1933年《證券法》第27A條、經修訂的1934年《證券交易法》第21E條以及其他適用的證券法所指的 “前瞻性信息” 和 “前瞻性陳述”(統稱爲 “前瞻性信息”)。前瞻性陳述通常以 “期望”、“預期”、“相信”、“打算”、“潛力”、“可能”、“將” 等詞語和類似表述來識別,但並非總是如此。此類陳述基於管理層當前的預期,本質上涉及許多已知和未知的風險、不確定性和假設,其中許多是我們無法控制的。前瞻性信息基於管理層當前的預期和信念,存在許多風險和不確定性,這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。本新聞稿包含前瞻性陳述,包括但不限於有關公司恢復遵守最低出價規則的能力、公司監控普通股收盤出價的意向以及公司考慮實施可用期權以恢復遵守最低出價規則的計劃,包括在必要時進行反向股票拆分的聲明。由於已知和未知的風險和不確定性,公司的實際業績和事件發生時間可能與此類前瞻性陳述中的預期存在重大差異,包括 (i) 公司可能無法滿足《納斯達克上市規則》規定的繼續上市要求的風險,(ii) 公司在延長的合規期內或未來任何其他合規期內可能不符合最低出價規則,(iii) 納斯達克不得給予公司退出救濟如有必要,以及 (iv) 公司可以如果需要任何此類救濟措施以及其他風險和不確定性,則最終無法滿足納斯達克適用的要求。

Beyond the foregoing, there are additional known and unknown risk factors and uncertainties, any of which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A further discussion of these risks and uncertainties facing InMed's stand-alone business is contained in InMed's most recent Annual Report on Form 10-K and other filings the Company makes with the Securities and Exchange Commission from time to time on www.sec.gov.

除上述內容外,還有其他已知和未知的風險因素和不確定性,其中任何一種都可能導致InMed的實際業績、業績或成就與本文所包含的前瞻性信息所表達或暗示的任何未來業績、業績或成就存在重大差異。有關InMed獨立業務面臨的這些風險和不確定性的進一步討論載於InMed最新的10-K表年度報告以及該公司不時向美國證券交易委員會提交的其他文件 www.sec.gov

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by applicable law.

除非適用法律要求,否則InMed不承擔任何修改或更新任何此類前瞻性信息或公開宣佈對本文包含的任何前瞻性信息進行任何修改或更新以反映未來業績、事件或發展的修訂結果的義務。

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/202334

要查看本新聞稿的源版本,請訪問 https://www.newsfilecorp.com/release/202334

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論